First Effective Group A Strep Vaccine Enters Phase 3 Trials: WHO Priority Pathogen

Why Has Developing a Strep A Vaccine Taken So Long?

Group A Streptococcus has been called the neglected pathogen — responsible for an estimated 500,000 deaths annually, predominantly in low- and middle-income countries, yet no vaccine has ever reached market. The major obstacle has been molecular mimicry: the M-protein on the streptococcal surface, which is the most immunogenic and logical vaccine target, shares structural similarities with human cardiac myosin, brain tissue, and joint synovium. Vaccine trials in the 1960s were halted when several participants developed rheumatic fever, creating decades of regulatory caution that effectively stalled the field.

The breakthrough by researchers at the Murdoch Children's Research Institute in Melbourne used advanced structural biology and computational epitope mapping to identify M-protein peptide fragments that elicit protective antibodies without triggering cross-reactive autoimmune responses. The multivalent vaccine candidate includes carefully selected peptides designed to cover the majority of circulating GAS emm types globally. Early-phase clinical trials showed robust immunogenicity with no autoimmune safety signals, and a subsequent Phase 2b trial conducted in thousands of children across multiple countries in the Southern Hemisphere confirmed meaningful vaccine efficacy against culture-confirmed GAS pharyngitis over two strep seasons. These results were the first to demonstrate that a GAS vaccine could work safely in children — a landmark for the field.

How Many People Die From Strep A Infections Each Year?

The true burden of GAS disease is staggering and disproportionately affects the world's poorest populations. According to widely cited estimates, there are approximately 600 million cases of GAS pharyngitis annually, hundreds of thousands of new cases of acute rheumatic fever each year, and over 30 million people living with rheumatic heart disease — a leading cause of cardiovascular death in people under 25 in sub-Saharan Africa, South Asia, and the Pacific Islands. An estimated 300,000 or more deaths per year are attributed to rheumatic heart disease alone, with additional deaths from invasive GAS infections including necrotizing fasciitis and streptococcal toxic shock syndrome.

In high-income countries, the well-documented winter 2022–2023 surge of invasive Group A Strep infections in children across the UK, Europe, and the US heightened public awareness and political urgency. The WHO has designated GAS as a priority pathogen for vaccine development, and major global health organizations including the Coalition for Epidemic Preparedness Innovations (CEPI) and the Bill & Melinda Gates Foundation have committed substantial funding to support advanced clinical trials in endemic settings. The Phase 3 trial is expected to enroll thousands of children aged 5–14 across multiple countries in Africa, Southeast Asia, and the Pacific over the coming years.